Tags

Type your tag names separated by a space and hit enter

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
J Neuroinflammation 2016; 13(1):280JN

Abstract

BACKGROUND

A subset of patients with neuromyelitis optica spectrum disorders (NMOSD) has been shown to be seropositive for myelin oligodendrocyte glycoprotein antibodies (MOG-IgG).

OBJECTIVE

To describe the epidemiological, clinical, radiological, cerebrospinal fluid (CSF), and electrophysiological features of a large cohort of MOG-IgG-positive patients with optic neuritis (ON) and/or myelitis (n = 50) as well as attack and long-term treatment outcomes.

METHODS

Retrospective multicenter study.

RESULTS

The sex ratio was 1:2.8 (m:f). Median age at onset was 31 years (range 6-70). The disease followed a multiphasic course in 80 % (median time-to-first-relapse 5 months; annualized relapse rate 0.92) and resulted in significant disability in 40 % (mean follow-up 75 ± 46.5 months), with severe visual impairment or functional blindness (36 %) and markedly impaired ambulation due to paresis or ataxia (25 %) as the most common long-term sequelae. Functional blindess in one or both eyes was noted during at least one ON attack in around 70 %. Perioptic enhancement was present in several patients. Besides acute tetra-/paraparesis, dysesthesia and pain were common in acute myelitis (70 %). Longitudinally extensive spinal cord lesions were frequent, but short lesions occurred at least once in 44 %. Fourty-one percent had a history of simultaneous ON and myelitis. Clinical or radiological involvement of the brain, brainstem, or cerebellum was present in 50 %; extra-opticospinal symptoms included intractable nausea and vomiting and respiratory insufficiency (fatal in one). CSF pleocytosis (partly neutrophilic) was present in 70 %, oligoclonal bands in only 13 %, and blood-CSF-barrier dysfunction in 32 %. Intravenous methylprednisolone (IVMP) and long-term immunosuppression were often effective; however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups after steroid withdrawal. Full recovery was achieved by plasma exchange in some cases, including after IVMP failure. Breakthrough attacks under azathioprine were linked to the drug-specific latency period and a lack of cotreatment with oral steroids. Methotrexate was effective in 5/6 patients. Interferon-beta was associated with ongoing or increasing disease activity. Rituximab and ofatumumab were effective in some patients. However, treatment with rituximab was followed by early relapses in several cases; end-of-dose relapses occurred 9-12 months after the first infusion. Coexisting autoimmunity was rare (9 %). Wingerchuk's 2006 and 2015 criteria for NMO(SD) and Barkhof and McDonald criteria for multiple sclerosis (MS) were met by 28 %, 32 %, 15 %, 33 %, respectively; MS had been suspected in 36 %. Disease onset or relapses were preceded by infection, vaccination, or pregnancy/delivery in several cases.

CONCLUSION

Our findings from a predominantly Caucasian cohort strongly argue against the concept of MOG-IgG denoting a mild and usually monophasic variant of NMOSD. The predominantly relapsing and often severe disease course and the short median time to second attack support the use of prophylactic long-term treatments in patients with MOG-IgG-positive ON and/or myelitis.

Authors+Show Affiliations

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.Department of Neurology, Ruhr University Bochum, Bochum, Germany.NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité University Medicine, Berlin, Germany. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité University Medicine Berlin, Berlin, Germany.Department of Neurology and Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.Department of Neurology, Ruhr University Bochum, Bochum, Germany.NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité University Medicine, Berlin, Germany. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité University Medicine Berlin, Berlin, Germany.Department of Neurology, Albert Ludwigs University, Freiburg, Germany.Department of Neurology, Albert Ludwigs University, Freiburg, Germany.Department of Neurology, Hannover Medical School, Hannover, Germany.Department of Neurology, Heinrich Heine University, Düsseldorf, Germany.Department of Neurology, Hannover Medical School, Hannover, Germany.Department of Neurology, University of Rostock, Rostock, Germany.Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.Department of Neurology, Julius Maximilians University, Würzburg, Germany.Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.IRCCS, C. Mondino National Neurological Institute, Pavia, Italy.Centro di Riferimento Regionale SM, Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano, Italy.Department of Neuroradiology, Charité University Medicine - Berlin, Berlin, Germany.Department of Neuroradiology, Ruhr University Bochum, Bochum, Germany.Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.Institute of Experimental Immunolog, affiliated to Euroimmun AG, Lübeck, Germany.Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.Department of Neurology, Hannover Medical School, Hannover, Germany.NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité University Medicine, Berlin, Germany. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité University Medicine Berlin, Berlin, Germany.Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27793206

Citation

Jarius, Sven, et al. "MOG-IgG in NMO and Related Disorders: a Multicenter Study of 50 Patients. Part 2: Epidemiology, Clinical Presentation, Radiological and Laboratory Features, Treatment Responses, and Long-term Outcome." Journal of Neuroinflammation, vol. 13, no. 1, 2016, p. 280.
Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280.
Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., ... Wildemann, B. (2016). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 13(1), p. 280.
Jarius S, et al. MOG-IgG in NMO and Related Disorders: a Multicenter Study of 50 Patients. Part 2: Epidemiology, Clinical Presentation, Radiological and Laboratory Features, Treatment Responses, and Long-term Outcome. J Neuroinflammation. 2016 09 27;13(1):280. PubMed PMID: 27793206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. AU - Jarius,Sven, AU - Ruprecht,Klemens, AU - Kleiter,Ingo, AU - Borisow,Nadja, AU - Asgari,Nasrin, AU - Pitarokoili,Kalliopi, AU - Pache,Florence, AU - Stich,Oliver, AU - Beume,Lena-Alexandra, AU - Hümmert,Martin W, AU - Ringelstein,Marius, AU - Trebst,Corinna, AU - Winkelmann,Alexander, AU - Schwarz,Alexander, AU - Buttmann,Mathias, AU - Zimmermann,Hanna, AU - Kuchling,Joseph, AU - Franciotta,Diego, AU - Capobianco,Marco, AU - Siebert,Eberhard, AU - Lukas,Carsten, AU - Korporal-Kuhnke,Mirjam, AU - Haas,Jürgen, AU - Fechner,Kai, AU - Brandt,Alexander U, AU - Schanda,Kathrin, AU - Aktas,Orhan, AU - Paul,Friedemann, AU - Reindl,Markus, AU - Wildemann,Brigitte, AU - ,, Y1 - 2016/09/27/ PY - 2016/04/01/received PY - 2016/09/09/accepted PY - 2016/10/30/pubmed PY - 2017/10/11/medline PY - 2016/10/30/entrez KW - Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) KW - Autoantibodies KW - Azathioprine KW - Barkhof criteria KW - Cerebrospinal fluid KW - Electrophysiology KW - Evoked potentials KW - Glatiramer acetate KW - IPND criteria KW - Infections KW - Interferon beta KW - International consensus diagnostic criteria for neuromyelitis optica spectrum disorders KW - Longitudinally extensive transverse myelitis KW - Magnetic resonance imaging KW - McDonald criteria KW - Methotrexate KW - Multiple sclerosis KW - Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) KW - Natalizumab KW - Neuromyelitis optica spectrum disorders (NMOSD) KW - Ofatumumab KW - Oligoclonal bands KW - Optic neuritis KW - Outcome KW - Pregnancy KW - Rituximab KW - Therapy KW - Transverse myelitis KW - Treatment KW - Vaccination KW - Wingerchuk criteria 2006 and 2015 SP - 280 EP - 280 JF - Journal of neuroinflammation JO - J Neuroinflammation VL - 13 IS - 1 N2 - BACKGROUND: A subset of patients with neuromyelitis optica spectrum disorders (NMOSD) has been shown to be seropositive for myelin oligodendrocyte glycoprotein antibodies (MOG-IgG). OBJECTIVE: To describe the epidemiological, clinical, radiological, cerebrospinal fluid (CSF), and electrophysiological features of a large cohort of MOG-IgG-positive patients with optic neuritis (ON) and/or myelitis (n = 50) as well as attack and long-term treatment outcomes. METHODS: Retrospective multicenter study. RESULTS: The sex ratio was 1:2.8 (m:f). Median age at onset was 31 years (range 6-70). The disease followed a multiphasic course in 80 % (median time-to-first-relapse 5 months; annualized relapse rate 0.92) and resulted in significant disability in 40 % (mean follow-up 75 ± 46.5 months), with severe visual impairment or functional blindness (36 %) and markedly impaired ambulation due to paresis or ataxia (25 %) as the most common long-term sequelae. Functional blindess in one or both eyes was noted during at least one ON attack in around 70 %. Perioptic enhancement was present in several patients. Besides acute tetra-/paraparesis, dysesthesia and pain were common in acute myelitis (70 %). Longitudinally extensive spinal cord lesions were frequent, but short lesions occurred at least once in 44 %. Fourty-one percent had a history of simultaneous ON and myelitis. Clinical or radiological involvement of the brain, brainstem, or cerebellum was present in 50 %; extra-opticospinal symptoms included intractable nausea and vomiting and respiratory insufficiency (fatal in one). CSF pleocytosis (partly neutrophilic) was present in 70 %, oligoclonal bands in only 13 %, and blood-CSF-barrier dysfunction in 32 %. Intravenous methylprednisolone (IVMP) and long-term immunosuppression were often effective; however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups after steroid withdrawal. Full recovery was achieved by plasma exchange in some cases, including after IVMP failure. Breakthrough attacks under azathioprine were linked to the drug-specific latency period and a lack of cotreatment with oral steroids. Methotrexate was effective in 5/6 patients. Interferon-beta was associated with ongoing or increasing disease activity. Rituximab and ofatumumab were effective in some patients. However, treatment with rituximab was followed by early relapses in several cases; end-of-dose relapses occurred 9-12 months after the first infusion. Coexisting autoimmunity was rare (9 %). Wingerchuk's 2006 and 2015 criteria for NMO(SD) and Barkhof and McDonald criteria for multiple sclerosis (MS) were met by 28 %, 32 %, 15 %, 33 %, respectively; MS had been suspected in 36 %. Disease onset or relapses were preceded by infection, vaccination, or pregnancy/delivery in several cases. CONCLUSION: Our findings from a predominantly Caucasian cohort strongly argue against the concept of MOG-IgG denoting a mild and usually monophasic variant of NMOSD. The predominantly relapsing and often severe disease course and the short median time to second attack support the use of prophylactic long-term treatments in patients with MOG-IgG-positive ON and/or myelitis. SN - 1742-2094 UR - https://www.unboundmedicine.com/medline/citation/27793206/MOG_IgG_in_NMO_and_related_disorders:_a_multicenter_study_of_50_patients__Part_2:_Epidemiology_clinical_presentation_radiological_and_laboratory_features_treatment_responses_and_long_term_outcome_ L2 - https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0718-0 DB - PRIME DP - Unbound Medicine ER -